Compare LEE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | ONCY |
|---|---|---|
| Founded | 1890 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 106.1M |
| IPO Year | N/A | 1999 |
| Metric | LEE | ONCY |
|---|---|---|
| Price | $3.43 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.4K | ★ 698.0K |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $562,341,000.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.45 | $0.33 |
| 52 Week High | $16.43 | $1.51 |
| Indicator | LEE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 49.67 |
| Support Level | $3.90 | $0.92 |
| Resistance Level | $4.43 | $1.04 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 6.16 | 74.82 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.